Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 571-577

  Molanaei, Hadi ^a,b   Stenvinkel, Peter ^a   Qureshi, Abdul Rashid ^a   Carrero, Juan Jesús ^a   Heimbürger, Olof ^a   Lindholm, Bengt ^a   Diczfalusy, Ulf ^b   Odar Cederlöf, Ingegerd ^b   Bertilsson, Leif ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alpha 1 acid glycoprotein; Alprazolam metabolism; C reactive protein; CYP3A4; Hemodialysis; Inflammation

Indexed keywords

4 HYDROXYALPRAZOLAM; 4BETA HYDROXYCHOLESTEROL; ALPHA HYDROXYCHOLESTEROL; ALPRAZOLAM; C REACTIVE PROTEIN; CHOLESTEROL; CONJUGATED 4 HYDROXYALPRAZOLAM; CYTOCHROME P450 3A4; DRUG METABOLITE; OROSOMUCOID; UNCLASSIFIED DRUG; UNCONJUGATED 4 HYDROXYALPRAZOLAM; UNCONJUGATED ALPHA HYDROXYCHOLESTEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; EVENING DOSAGE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADULT; AGED; ALGORITHMS; ALPRAZOLAM; ANTI-ANXIETY AGENTS; BIOLOGICAL MARKERS; BIOTRANSFORMATION; C-REACTIVE PROTEIN; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYLATION; MALE; MIDDLE AGED; OROSOMUCOID; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84864289543     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1163-8     Document Type: Article

References (31)

1. Morgan E (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434-438
2. Xu D, Wang J, Sun M, Chen Y, Wei W (2006) Lipopolysaccharide downregulates the expressions of intestinal pregnane X receptor and cytochrome P450 3a11. Eur J Pharmacol 536:162-170
3. Robertson G, Liddle C, Clarke S (2008) Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 83:894-897 (Pubitemid 351704929)
4. Kacevska M, Robertson G, Clarke S, Liddle C (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 4:137-149 (Pubitemid 351308413)
5. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 36(2):205-216 (Pubitemid 351185732)
6. Nolin T, Naud J, Leblond F, Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898-903 (Pubitemid 351704931)
7. Stenvinkel P, Carrero J, Axelsson J, Lindholm B, Heimbürger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3:505-521
8. Säwe J, Kager L, Svensson Eng J, Rane A (1985) Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol 19:495-501 (Pubitemid 16254591)
9. Molanaei H, Carrero JJ, Heimburger O, Nordfors L, Lindholm B, Stenvinkel P, Odar-Cederlof I, Bertilsson L (2010) Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. Eur J Clin Pharmacol 66:269-273
10. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 22:53-71 (Pubitemid 34030888)
11. Allqvist A, Miura J, Bertilsson L, Mirghani RA (2007) Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol 63:173-179 (Pubitemid 46147059)
12. Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD (1999) Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931-944 (Pubitemid 29454386)
13. Allqvist A (2010) The role of CYP3A/5 in alprazolam metabolism. PhD thesis. Karolinska Institutet, Stockholm
14. Allqvist A, Wennerholm A, Svensson J, Mirghani R (2005) Simultaneous quantification of alprazolam, 4- and alpha-hydroxyalprazolam in plasma samples using liquid chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 814:127-131 (Pubitemid 40017944)
15. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 276:38685-38689
16. Wennerholm A, Allqvist A, Svensson J, Gustafsson L, Mirghani R, Bertilsson L (2005) Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. Eur J Clin Pharmacol 61:113-118 (Pubitemid 40674743)
17. Dawson G, Jue S, Brogden R (1984) Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 27:132-147 (Pubitemid 14223114)
18. Diczfalusy U, Nylén H, Elander P, Bertilsson L (2011) 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71:183-189
19. Piafsky K, Borgá O, Odar-Cederlöf I, Johansson C, Sjöqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med 299:1435-1439 (Pubitemid 9192306)
20. Petrovic V, Teng S, Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111 (Pubitemid 46683180)
21. Slaviero K, Clarke S, Rivory L (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224-232 (Pubitemid 36503320)
22. Renton K (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1:629-640
23. Diczfalusy U, Miura J, Roh H, Mirghani R, Sayi J, Larsson H, Bodin K, Allqvist A, Jande M, Kim J, Aklillu E, Gustafsson L, Bertilsson L (2008) 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18:201-208 (Pubitemid 351323234)
24. Kanebratt K, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson T, Bertilsson L (2008) Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 84:589-594
25. Diczfalusy U, Kanebratt K, Bredberg E, Andersson T, Böttiger Y, Bertilsson L (2009) 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 67:38-43
26. Foley R, Parfrey P, Sarnak M (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119 (Pubitemid 28527268)
27. Cheung A, Sarnak M, Yan G, Dwyer J, Heyka R, Rocco M, Teehan B, Levey A (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362 (Pubitemid 30429882)
28. Sarnak M, Levey A (2000) Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35:S117-S131 (Pubitemid 30183825)
29. Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4(Suppl 1):S49-S55
30. Carrero JJ, Stenvinkel P (2010) Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 23:498-509
31. Carrero JJ, Yilmaz MI, Lindholm B, Stenvinkel P (2008) Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 26:291-299 (Pubitemid 351748064)